Nakayama, Tetsuo <br/><br/>
Immunogenicity and safety of the new MMR vaccine containing measles AIK-C, rubella Takahashi, and mumps RIT4385 strains in Japanese children: a randomized phase I/II clinical trial.  [electronic resource] 

 -  Human vaccines & immunotherapeutics  2019 
 - 1139-1144 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2164-554X 
<br/><br/><label>Standard No.: </label>10.1080/21645515.2019.1578591  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antibodies, Neutralizing--blood<br/>Antibodies, Viral--blood<br/>Female<br/>Humans<br/>Immunogenicity, Vaccine<br/>Infant<br/>Japan<br/>Male<br/>Measles--prevention & control<br/>Measles-Mumps-Rubella Vaccine--administration & dosage<br/>Mumps--prevention & control<br/>Rubella--prevention & control<br/>Seroconversion<br/>Vaccination